For many diseases and disorders, gene therapy using adeno-associated viruses (AAVs) has been relatively successful in transporting specific genes across the body. However, with the blood-brain barrier being highly selective of what enters the brain, it will often reject AAVs from entering. When AAVs are denied entry to the brain patients do not receive the proper gene therapy needed to treat their disease. This is why a team of researchers from MIT and Harvard University set out to engineer a new AAV that could cross the blood-brain barrier with ease.
To do this the team of researchers developed a variety of new AAVs to specifically find one that would bind to the transferrin protein receptor (TfR1), which is found in high quantities on the blood-brain barrier and is responsible for bringing iron into the brain.
While testing their newly developed TfR1-bound AAV on mice, the researchers found AAVs crossing the blood-brain barrier at levels 6-12 times higher than AAVs that are not TfR1-bound. Another significant observation was that the AAV's increased entry methods were only found for the central nervous system. Finally, the researchers found that when trying to deliver GBA1 into the brains of mice the TfR1-bound AAVs delivered 30 times more copies of GBA1.
The development of TfR1-bound AAVs is extremely significant for the increased effectiveness of AAV gene therapy. Personally, I think this breakthrough should be closely monitored to ensure that using TfR1-bound AAVs does not cause harm in the long run by potentially creating competition for iron attempting to cross the blood-brain barrier. This is important to monitor since a deficiency of iron can lead to many motor and cognitive impairments.
https://registries.ncats.nih.gov/glossary/adeno-associated-virus-gene-therapy/
/identifying-schizophrenia-in-children-4155780-88bc55cd9a3247e1b794167e6a0d4667.png)
